Roche Genentech Acquisition Explained

Roche acquired Genentech in 2009 for $46.8 billion, creating one of the world's largest biotech companies.

Genentech was founded in 1976 and was known for its innovative approach to biotechnology.

The acquisition allowed Roche to expand its portfolio of pharmaceuticals and biologics.

Roche's acquisition of Genentech marked a significant milestone in the history of biotechnology.

Genentech's expertise in biologics was a major draw for Roche, which sought to strengthen its position in the market.

The acquisition helped Roche to become a leader in the development of cancer treatments.

Roche's purchase of Genentech was a strategic move to expand its presence in the US market.

The acquisition provided Roche with access to Genentech's pipeline of innovative treatments.

Roche's acquisition of Genentech was a significant deal that took place on March 25, 2009, with a total value of $46.8 billion.

The acquisition was structured as a stock swap, with Roche exchanging 0.9284 of its American Depositary Shares (ADS) for each Genentech share.

Roche acquired 100% of Genentech's outstanding shares, which was a major move for the company.

Genentech's CEO, Bill Anderson, became the head of Roche's Pharmaceuticals Division after the acquisition.

Roche's acquisition of Genentech was the largest biotech deal in history at the time.

The deal was completed in just 10 weeks, a remarkably short timeframe for an acquisition of this size.

Roche's acquisition of Genentech has had a lasting impact on the biotech industry.

Genentech's successful cancer treatment, Avastin, was a major factor in Roche's decision to acquire the company.

The acquisition has allowed Roche to expand its presence in the US market.

Check this out: Bill Ackman Special Purpose Acquisition Company

Roche's acquisition of Genentech in 2009 was a game-changer for the company.

Roche paid $46.8 billion for Genentech in 2009, reflecting a 4.4x revenue multiple, which is a significant investment.

Genentech's total sales were on the rise, growing from $7.6 billion in 2006 to $10.5 billion in 2008.

The same blockbuster drugs that accounted for close to 70% of Genentech's total sales in 2008 continued to see stellar growth over the next 10 years.

By 2018, Avastin, Rituxan, Herceptin, and Lucentis generated a whopping $21.1 billion in sales for Roche.

This growth is impressive, considering the $46.8 billion price paid by Roche for Genentech's entire portfolio.

Roche's acquisition of Genentech was a good deal for the company, but the same blockbuster drugs now face biosimilar competition.

Here's a breakdown of the sales figures for the four drugs in 2018:

Roche's acquisition of Genentech in 2009 was a massive deal, with the company paying $46.8 billion for the biotech firm.

The acquisition was a good deal for Roche, as it was able to grow the sales of Genentech's top drugs from $7 billion in 2008 to over $21 billion in 2018.

Roche's CFO was able to finance the acquisition by issuing a record $42 billion bond in February 2009, with $32 billion of that being sold at various maturities from 1 year to 30 years.

The bond issue was a bold move, considering the uncertainty in the financial markets at the time.

Genentech's total sales were on the rise before the acquisition, growing from $7.6 billion in 2006 to $10.5 billion in 2008.

The company's top drugs, including Avastin, Herceptin, Rituxan, and Lucentis, accounted for close to 70% of its total sales.

Here are the key financial metrics of the acquisition: